Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Identifieur interne : 000644 ( PubMed/Checkpoint ); précédent : 000643; suivant : 000645Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Auteurs : Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. FacherisSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- Amantadine (therapeutic use), Analysis of Variance, Animals, Antiparkinson Agents (adverse effects), Disease Models, Animal, Dose-Response Relationship, Drug, Drug Therapy, Combination, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Excitatory Amino Acid Antagonists (therapeutic use), Female, Imidazoles (therapeutic use), Levodopa (adverse effects), MPTP Poisoning (drug therapy), Macaca fascicularis.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Amantadine, Excitatory Amino Acid Antagonists, Imidazoles.
- drug therapy : Dyskinesia, Drug-Induced, MPTP Poisoning.
- etiology : Dyskinesia, Drug-Induced.
- Analysis of Variance, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Macaca fascicularis.
Abstract
Amantadine, an N-methyl-D-aspartate glutamate receptor antagonist, is currently the only pharmacological treatment for levodopa-induced dyskinesia (LID) in Parkinson's disease (PD), but causes adverse effects on the central nervous system at therapeutic doses. Fenobam, a negative modulator of metabotropic glutamate receptor subtype 5, has recently been reported to attenuate LID in MPTP-treated macaques. The aim of the current study was to investigate the treatment interactions of fenobam and amantadine on LID in the MPTP-treated macaque model of PD. The antidyskinetic and -parkinsonian effects were measured after administration of fenobam (10-30 mg/kg) and amantadine (10-30 mg/kg) alone and in combination. Fenobam (30 mg/kg) and amantadine (30 mg/kg) alone reduced LID, whereas lower doses of either drug did not cause any significant effects. A combined treatment of fenobam and amantadine at subthreshold doses (10 and 20 mg/kg) significantly reduced LID without worsening PD disability. These data suggest that a low-dose combination of fenobam and amantadine can be used for alleviating dyskinesia without causing adverse motor effects. Such combined therapies may offer a new therapeutic strategy for treatment of LID in PD patients.
DOI: 10.1002/mds.25859
PubMed: 24610195
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24610195Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.</title><author><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name><affiliation wicri:level="4"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, United Kingdom; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester, United Kingdom; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux</wicri:regionArea><placeName><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName><placeName><settlement type="city">Bordeaux</settlement><region type="region" nuts="2">Aquitaine</region></placeName></affiliation></author><author><name sortKey="Pioli, Elsa" sort="Pioli, Elsa" uniqKey="Pioli E" first="Elsa" last="Pioli">Elsa Pioli</name></author><author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name></author><author><name sortKey="Mcguire, Steve" sort="Mcguire, Steve" uniqKey="Mcguire S" first="Steve" last="Mcguire">Steve Mcguire</name></author><author><name sortKey="Dufour, Audrey" sort="Dufour, Audrey" uniqKey="Dufour A" first="Audrey" last="Dufour">Audrey Dufour</name></author><author><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B" last="Sherer">Todd B. Sherer</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Facheris, Maurizio F" sort="Facheris, Maurizio F" uniqKey="Facheris M" first="Maurizio F" last="Facheris">Maurizio F. Facheris</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24610195</idno><idno type="pmid">24610195</idno><idno type="doi">10.1002/mds.25859</idno><idno type="wicri:Area/PubMed/Corpus">000559</idno><idno type="wicri:Area/PubMed/Curation">000559</idno><idno type="wicri:Area/PubMed/Checkpoint">000644</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.</title><author><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name><affiliation wicri:level="4"><nlm:affiliation>Motac Neuroscience Ltd, Manchester, United Kingdom; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Motac Neuroscience Ltd, Manchester, United Kingdom; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux</wicri:regionArea><placeName><settlement type="city">Bordeaux</settlement></placeName><orgName type="university">Université de Bordeaux</orgName><placeName><settlement type="city">Bordeaux</settlement><region type="region" nuts="2">Aquitaine</region></placeName></affiliation></author><author><name sortKey="Pioli, Elsa" sort="Pioli, Elsa" uniqKey="Pioli E" first="Elsa" last="Pioli">Elsa Pioli</name></author><author><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name></author><author><name sortKey="Mcguire, Steve" sort="Mcguire, Steve" uniqKey="Mcguire S" first="Steve" last="Mcguire">Steve Mcguire</name></author><author><name sortKey="Dufour, Audrey" sort="Dufour, Audrey" uniqKey="Dufour A" first="Audrey" last="Dufour">Audrey Dufour</name></author><author><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B" last="Sherer">Todd B. Sherer</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Facheris, Maurizio F" sort="Facheris, Maurizio F" uniqKey="Facheris M" first="Maurizio F" last="Facheris">Maurizio F. Facheris</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (therapeutic use)</term><term>Analysis of Variance</term><term>Animals</term><term>Antiparkinson Agents (adverse effects)</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Excitatory Amino Acid Antagonists (therapeutic use)</term><term>Female</term><term>Imidazoles (therapeutic use)</term><term>Levodopa (adverse effects)</term><term>MPTP Poisoning (drug therapy)</term><term>Macaca fascicularis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Excitatory Amino Acid Antagonists</term><term>Imidazoles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Macaca fascicularis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Amantadine, an N-methyl-D-aspartate glutamate receptor antagonist, is currently the only pharmacological treatment for levodopa-induced dyskinesia (LID) in Parkinson's disease (PD), but causes adverse effects on the central nervous system at therapeutic doses. Fenobam, a negative modulator of metabotropic glutamate receptor subtype 5, has recently been reported to attenuate LID in MPTP-treated macaques. The aim of the current study was to investigate the treatment interactions of fenobam and amantadine on LID in the MPTP-treated macaque model of PD. The antidyskinetic and -parkinsonian effects were measured after administration of fenobam (10-30 mg/kg) and amantadine (10-30 mg/kg) alone and in combination. Fenobam (30 mg/kg) and amantadine (30 mg/kg) alone reduced LID, whereas lower doses of either drug did not cause any significant effects. A combined treatment of fenobam and amantadine at subthreshold doses (10 and 20 mg/kg) significantly reduced LID without worsening PD disability. These data suggest that a low-dose combination of fenobam and amantadine can be used for alleviating dyskinesia without causing adverse motor effects. Such combined therapies may offer a new therapeutic strategy for treatment of LID in PD patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24610195</PMID><DateCreated><Year>2014</Year><Month>05</Month><Day>06</Day></DateCreated><DateCompleted><Year>2014</Year><Month>12</Month><Day>19</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>772-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25859</ELocationID><Abstract><AbstractText>Amantadine, an N-methyl-D-aspartate glutamate receptor antagonist, is currently the only pharmacological treatment for levodopa-induced dyskinesia (LID) in Parkinson's disease (PD), but causes adverse effects on the central nervous system at therapeutic doses. Fenobam, a negative modulator of metabotropic glutamate receptor subtype 5, has recently been reported to attenuate LID in MPTP-treated macaques. The aim of the current study was to investigate the treatment interactions of fenobam and amantadine on LID in the MPTP-treated macaque model of PD. The antidyskinetic and -parkinsonian effects were measured after administration of fenobam (10-30 mg/kg) and amantadine (10-30 mg/kg) alone and in combination. Fenobam (30 mg/kg) and amantadine (30 mg/kg) alone reduced LID, whereas lower doses of either drug did not cause any significant effects. A combined treatment of fenobam and amantadine at subthreshold doses (10 and 20 mg/kg) significantly reduced LID without worsening PD disability. These data suggest that a low-dose combination of fenobam and amantadine can be used for alleviating dyskinesia without causing adverse motor effects. Such combined therapies may offer a new therapeutic strategy for treatment of LID in PD patients.</AbstractText><CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Wai Kin D</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Motac Neuroscience Ltd, Manchester, United Kingdom; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pioli</LastName><ForeName>Elsa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qin</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dufour</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sherer</LastName><ForeName>Todd B</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Bezard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Facheris</LastName><ForeName>Maurizio F</ForeName><Initials>MF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>07O6708M02</RegistryNumber><NameOfSubstance UI="C032794">fenobam</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000547">Amantadine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018691">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007093">Imidazoles</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020267">MPTP Poisoning</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008252">Macaca fascicularis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson</Keyword><Keyword MajorTopicYN="N">dyskinesia</Keyword><Keyword MajorTopicYN="N">mGluR5 antagonist</Keyword><Keyword MajorTopicYN="N">macaque</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24610195</ArticleId><ArticleId IdType="doi">10.1002/mds.25859</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li></region><settlement><li>Bordeaux</li></settlement><orgName><li>Université de Bordeaux</li></orgName></list><tree><noCountry><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><name sortKey="Dufour, Audrey" sort="Dufour, Audrey" uniqKey="Dufour A" first="Audrey" last="Dufour">Audrey Dufour</name><name sortKey="Facheris, Maurizio F" sort="Facheris, Maurizio F" uniqKey="Facheris M" first="Maurizio F" last="Facheris">Maurizio F. Facheris</name><name sortKey="Li, Qin" sort="Li, Qin" uniqKey="Li Q" first="Qin" last="Li">Qin Li</name><name sortKey="Mcguire, Steve" sort="Mcguire, Steve" uniqKey="Mcguire S" first="Steve" last="Mcguire">Steve Mcguire</name><name sortKey="Pioli, Elsa" sort="Pioli, Elsa" uniqKey="Pioli E" first="Elsa" last="Pioli">Elsa Pioli</name><name sortKey="Sherer, Todd B" sort="Sherer, Todd B" uniqKey="Sherer T" first="Todd B" last="Sherer">Todd B. Sherer</name></noCountry><country name="France"><noRegion><name sortKey="Ko, Wai Kin D" sort="Ko, Wai Kin D" uniqKey="Ko W" first="Wai Kin D" last="Ko">Wai Kin D. Ko</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000644 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000644 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24610195
|texte= Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24610195" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |